Repligen (RGEN) Could Be 20% Undervalued After Q1 Guidance Cooled Growth Hopes

Repligen earnings reaction puts guidance in focus

Repligen (RGEN) came back on investor radar after Brown Capital Management flagged the stock as a key detractor, following the market reaction to its Q1 2026 earnings release and moderated growth guidance.

See our latest analysis for Repligen.

At a share price of $147.01, Repligen has seen strong short term momentum, with 7 day and 30 day share price returns of 11.35% and 29.90%. This contrasts with a year to date share price decline of 10.55% and a mixed longer term total shareholder return profile, including an 18.98% gain over 1 year and a 27.19% decline over 5 years. This suggests sentiment has recently improved following a slower period.

If Q1 earnings and guidance have you reassessing growth stories in healthcare, it may be worth broadening your research to other potential opportunities through our 39 healthcare AI stocks

With Repligen trading at $147.01 and only a small model based intrinsic discount indicated, plus a roughly 20% gap to analyst targets, you have to ask: is there real upside left here, or is the market already pricing in future growth?

Most Popular Narrative: 20% Undervalued

With Repligen at $147.01 against a widely followed fair value narrative of about $183.88, the current price sits below what that framework suggests, putting the long term earnings and margin path firmly under the spotlight.

Repligen is investing in expanding dual manufacturing (U.S. and Europe) and increasing APAC presence to address growing customer demand for greater supply chain security and regionalization, which should drive resilient sales globally and reduce revenue concentration risk.

Continued product launches (new resins, Metenova single-use mixers, integrated PAT platforms) and recent acquisitions (e.g., 908 bioprocessing) are building additional recurring consumable pull through and expanding the addressable market, directly supporting long term revenue and operating margin growth.

Read the complete narrative.

Want to understand why this Repligen story points to a higher fair value? The core of the narrative leans on faster top line expansion, rising margins and a future earnings profile that assumes the market will keep paying a premium multiple. Curious how those moving parts fit together into one price target path? The full narrative lays out the exact growth and profitability curve behind that $183.88 figure.

Result: Fair Value of $183.88 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Repligen's reliance on smaller biotech customers and exposure to gene therapy and AAV demand mean that any prolonged funding pressure or weakness in these modalities could challenge this upside story.

Find out about the key risks to this Repligen narrative.

Another View: Repligen multiples paint a tighter picture

While the Repligen fair value narrative points to upside, the current P/S of 10.9x is far above the US Life Sciences industry average of 3.8x and above the peer average of 5.9x. It also sits well ahead of the 5.1x fair ratio, which suggests valuation risk if sentiment cools.

When a stock trades at roughly double a peer group on revenue, even a solid growth story can face pressure if expectations slip. The key question is whether you believe Repligen can keep justifying a P/S that is this far ahead of where the fair ratio suggests the market could move toward over time.

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If the mix of optimism and concern around Repligen feels finely balanced, move quickly, review the underlying data, and weigh both sides for yourself. You can start with the 3 key rewards and 1 important warning sign

Looking for more investment ideas beyond Repligen?

If Repligen has sharpened your focus on quality, use that momentum and line up a few fresh ideas before the next round of earnings headlines hits.

• Target potential mispricing by scanning companies that combine quality fundamentals with attractive pricing through the 44 high quality undervalued stocks.
• Strengthen your income stream by reviewing companies with higher yields that may help support regular cash returns via the 8 dividend fortresses.
• Dial up resilience in your portfolio by filtering for companies with conservative balance sheets and solid fundamentals using the solid balance sheet and fundamentals stocks screener (48 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com